GlobeNewswire — Public Companies·US·
The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech
NeOnc (NASDAQ: NTHI) delivered a brain cancer drug and non-invasive intranasal delivery double header breakthrough
Read releases like this the second they cross the wire.
1400+ feeds from 80+ newswires in one live cockpit — saved searches, instant alerts, AI summaries. 72-hour free trial, no card required.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live on PPN World.
PPN Source →Shared via PPN World — real-time press release intelligence.